SCHEMBL6773280

SCHEMBL6773280

COC(=O)c1cccc(NC(=NC#N)NCc2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
HPGD P15428 1/20 0.55
RAB9A P51151 5/20 0.53
KMT2A Q03164 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
MEN1 O00255 3/20 0.53
MAPT P10636 1/20 0.53
HIF1A Q16665 1/20 0.50
NPC1 O15118 1/20 0.49
MITF O75030 1/20 0.49
MAPK1 P28482 1/20 0.49
CASR P41180 2/20 0.48
HSD17B10 Q99714 1/20 0.48
HTT P42858 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6773278 1.00 ALDH1A1 (0.55) ALDH1A1HPGDRAB9AKMT2ASMN1; SMN2
SCHEMBL6783217 0.88 TSHR (0.57) ALDH1A1HPGDRAB9AKMT2ASMN1; SMN2
SCHEMBL6783215 0.88 TSHR (0.57) ALDH1A1HPGDRAB9AKMT2ASMN1; SMN2
SCHEMBL6772591 0.86 RAB9A (0.51) ALDH1A1HPGDRAB9AKMT2ASMN1; SMN2
SCHEMBL6772589 0.86 RAB9A (0.51) ALDH1A1HPGDRAB9AKMT2ASMN1; SMN2
SCHEMBL6773986 0.84 RAB9A (0.56) ALDH1A1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL6773990 0.84 RAB9A (0.56) ALDH1A1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL6772415 0.82 RAB9A (0.59) ALDH1A1HPGDRAB9AKMT2ASMN1; SMN2
SCHEMBL6772413 0.82 RAB9A (0.59) ALDH1A1HPGDRAB9AKMT2ASMN1; SMN2
SCHEMBL27426573 0.81 RAB9A (0.46) ALDH1A1HPGDRAB9AKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed